Tyr304
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr304  -  PRMT5 (human)

Site Information
yELFAKGyEDyLQsP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 18545701

In vivo Characterization
Methods used to characterize site in vivo:
phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
bone cancer ( 1 ) , leukemia ( 1 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 1 )
Relevant cell line - cell type - tissue:
'hematopoietic progenitor, CD34+'-blood ( 1 ) , HEK293T (epithelial) ( 1 ) , HEL (erythroid) ( 1 ) , HeLa (cervical) ( 1 ) , U2OS (bone cell) ( 1 )

Upstream Regulation
Putative in vivo kinases:
JAK2 (human) ( 1 )
Kinases, in vitro:
JAK2 (human) ( 1 )
Treatments:
fedratinib ( 1 ) , JAK_inhibitor_I ( 1 ) , lestaurtinib ( 1 )

Downstream Regulation
Effects of modification on PRMT5:
enzymatic activity, inhibited ( 1 ) , molecular association, regulation ( 1 )
Effects of modification on biological processes:
carcinogenesis, altered ( 1 ) , cell growth, altered ( 1 )
Inhibit interaction with:
PRMT5 (human) ( 1 )

References 

1

Liu F, et al. (2011) JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell 19, 283-94
21316606   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.